Endogenous GLP-1 level was found to be increased in patients with high cardiovascular risk, suggesting it represent a contra-regulatory response in states of metabolic disorder, hepertriglyceridemia and insulin resistance[45]. Here, GLP1R is linked to metabolic disease.